Quantum X Labs Q2 FY26 operating loss widens to $1.95 million; revenue falls 28.82% to $646,000 in H1 FY26

• Quantum X Labs posted revenue of $293,000 for the quarter ended June 30, 2026, down 20.81% year over year.
• Research and development expense climbed to $185,000 from $20,000, reflecting consolidation of Quantum Israel after the March 2026 acquisition.
• General and administrative expense rose to $1.02 million from $558,000, on higher professional services costs and consolidation-related expenses.
• Net financial expense narrowed to $113,000 from $7.66 million, as prior-year results included fair-value financing expenses tied to facility agreements.
• Results included a $3.83 million gain from deconsolidating CliniQuantum following a June 2026 third-party purchase of about 54.01% of its equity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum X Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037811), on August 13, 2026, and is solely responsible for the information contained therein.